Tong Dai   Assistant Professor

  • +1 646 962 6200

Dr. Dai joined The Gastrointestinal Oncology program at Weill Cornell Medical College/ New York-Presbyterian Hospital in 2014, and provides care to patients with cancers of the gastrointestinal tract.

Dr. Dai graduated from Shanghai Medical University (now Fudan University School of Medicine) in 1993, and from Medical College of Ohio (now University of Toledo Health Science Campus) in 2003. During his graduate school study, Dr. investigated role of CEACAM1 (Carcinoembryonic antigen-related cell adhesion molecule 1) in insulin resistance and diabetes using transgenic and knockout mouse models.

After obtain his Ph.D. in Molecular Basis of Disease, Dr. Dai trained with breast cancer research expert Dr. Lewis Chodosh at University of Pennsylvania, Abramson Cancer Research Institute, and generated AKT2 transgenic mouse to investigate mechanism of breast cancer. He later moved to Yale University as Associate Research Scientist and worked with Dr. Edward Chu, Deputy Director of Yale Cancer Center and an expert in colorectal cancer research and treatment.

Dr. Dai completed his Internal Medicine Residency training at Yale University-affiliated Hospital of Saint Raphael in 2011, and Hematology-Oncology Fellowship at Albert Einstein School of Medicine-affiliated Montefiore Medical Center in 2014. When he was an Internal Medicine Resident, Dr. Dai was invited by American Association for Cancer Research (AACR) to serve as Chairperson for “Notch Signaling: Finding New Targets of Cancer Treatment” as part of “Basic Science/Clinical Interface: Pathways to Progress” session at AACR annual meeting in 2009. He also authored a review on Notch signaling and cancer for the annual meeting educational book. Upon his completion of Hematology-Oncology Fellowship, Dr. Dai was invited to review manuscripts for the journal Cancer Letters.

In the era of great advances in the understanding of signaling pathways, cancer genetics, cancer immunology, tumor microenvironment, role of inflammation in cancer, and discovery of new therapeutics targeting key pathways that are involved in cancer progression, Dr. Dai’s expertise in molecular biology and cancer biology, and vigorous training in medical oncology enable him to provide cancer patients and their family broad knowledge and perspectives about cancer. He works within multidiscipline team to provide passionate and comprehensive care to cancer patients. In addition, Dr. Dai is also involved in translational and clinical research on gastrointestinal cancers.



Sort by

Selected publications

  • Chemoradiation in esophageal cancerBest Practice and Research: Clinical Gastroenterology. 2015 In Process GET IT
  • Targeting MET in cancer: Obstacles and potentialsTranslational Biomedicine2015 Academic Article
  • The Role of 18F-FDG PET Imaging in Upper Gastrointestinal MalignanciesCurrent treatment options in oncology. 2014 In Process GET IT
  • Ruxolitinib withdrawal syndrome leading to tumor lysis.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology2013 Academic Article GET IT
    Times cited: 7



full name

  • Dr. Tong Dai,

primary email



eRA Commons ID



Primary Affiliation

  • Weill Cornell Medical College, Cornell University